Takahashi Tetta, Tomonobu Nahoko, Kinoshita Rie, Yamamoto Ken-Ichi, Murata Hitoshi, Komalasari Ni Luh Gede Yoni, Chen Youyi, Jiang Fan, Gohara Yuma, Ochi Toshiki, Ruma I Made Winarsa, Sumardika I Wayan, Zhou Jin, Honjo Tomoko, Sakaguchi Yoshihiko, Yamauchi Akira, Kuribayashi Futoshi, Kondo Eisaku, Inoue Yusuke, Futami Junichiro, Toyooka Shinichi, Zamami Yoshito, Sakaguchi Masakiyo
Department of Cell Biology, Okayama University Graduate School of Medicine, Dentistry and Pharmaceutical Sciences, Okayama, Japan.
Department of Pharmacy, Okayama University Hospital, Okayama, Japan.
Front Oncol. 2024 Mar 26;14:1371342. doi: 10.3389/fonc.2024.1371342. eCollection 2024.
Our earlier research revealed that the secreted lysyl oxidase-like 4 (LOXL4) that is highly elevated in triple-negative breast cancer (TNBC) acts as a catalyst to lock annexin A2 on the cell membrane surface, which accelerates invasive outgrowth of the cancer through the binding of integrin-β1 on the cell surface. However, whether this machinery is subject to the LOXL4-mediated intrusive regulation remains uncertain.
Cell invasion was assessed using a transwell-based assay, protein-protein interactions by an immunoprecipitation-Western blotting technique and immunocytochemistry, and plasmin activity in the cell membrane by gelatin zymography.
We revealed that cell surface annexin A2 acts as a receptor of plasminogen via interaction with S100A10, a key cell surface annexin A2-binding factor, and S100A11. We found that the cell surface annexin A2/S100A11 complex leads to mature active plasmin from bound plasminogen, which actively stimulates gelatin digestion, followed by increased invasion.
We have refined our understanding of the role of LOXL4 in TNBC cell invasion: namely, LOXL4 mediates the upregulation of annexin A2 at the cell surface, the upregulated annexin 2 binds S100A11 and S100A10, and the resulting annexin A2/S100A11 complex acts as a receptor of plasminogen, readily converting it into active-form plasmin and thereby enhancing invasion.
我们早期的研究表明,在三阴性乳腺癌(TNBC)中高度升高的分泌型赖氨酰氧化酶样4(LOXL4)作为一种催化剂,将膜联蛋白A2锁定在细胞膜表面,通过与细胞表面整合素-β1结合加速癌症的侵袭性生长。然而,这种机制是否受LOXL4介导的侵袭调控仍不确定。
使用基于Transwell的分析评估细胞侵袭,通过免疫沉淀-蛋白质印迹技术和免疫细胞化学评估蛋白质-蛋白质相互作用,通过明胶酶谱法评估细胞膜中的纤溶酶活性。
我们发现细胞表面膜联蛋白A2通过与关键的细胞表面膜联蛋白A2结合因子S100A10和S100A11相互作用,作为纤溶酶原的受体。我们发现细胞表面膜联蛋白A2/S100A11复合物可使结合的纤溶酶原产生成熟的活性纤溶酶,后者可积极刺激明胶消化,随后侵袭增加。
我们对LOXL4在TNBC细胞侵袭中的作用有了更深入的理解:即,LOXL4介导细胞表面膜联蛋白A2的上调,上调的膜联蛋白2与S100A11和S100A10结合,产生的膜联蛋白A2/S100A11复合物作为纤溶酶原的受体,将其迅速转化为活性形式的纤溶酶,从而增强侵袭。